

Rating: BUY | CMP: Rs1,829 | TP: Rs2,150

February 18, 2026

## Q3FY26 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

### Change in Estimates

	Current FY27E	Previous FY28E	Current FY27E	Previous FY28E
Rating	BUY	BUY		
Target Price	2,150	2,100		
Sales (Rs. m)	1,06,115	1,19,327	1,03,417	1,16,157
% Chng.	2.6	2.7		
EBITDA (Rs. m)	21,903	25,503	20,468	23,949
% Chng.	7.0	6.5		
EPS (Rs.)	60.2	72.4	57.7	68.2
% Chng.	4.4	6.2		

### Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	54,830	78,998	1,06,115	1,19,327
EBITDA (Rs. m)	12,764	16,724	21,903	25,503
Margin (%)	23.3	21.2	20.6	21.4
PAT (Rs. m)	7,898	8,389	12,312	14,796
EPS (Rs.)	38.6	41.1	60.2	72.4
Gr. (%)	0.0	6.2	46.8	20.2
DPS (Rs.)	5.2	5.8	6.4	7.0
Yield (%)	0.3	0.3	0.3	0.4
RoE (%)	24.5	24.3	25.2	24.2
RoCE (%)	19.6	17.5	19.0	20.6
EV/Sales (x)	7.1	5.2	3.8	3.4
EV/EBITDA (x)	30.5	24.6	18.6	15.7
PE (x)	47.3	44.6	30.4	25.3
P/BV (x)	10.3	8.6	6.9	5.5

### Key Data

	NARY.BO   NARH IN
52-W High / Low	Rs.2,372 / Rs.1,296
Sensex / Nifty	83,451 / 25,725
Market Cap	Rs.374bn/ \$ 4,122m
Shares Outstanding	204m
3M Avg. Daily Value	Rs.1438.97m

### Shareholding Pattern (%)

Promoter's	63.27
Foreign	11.10
Domestic Institution	7.92
Public & Others	17.71
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	(4.6)	0.9	37.9
Relative	(4.4)	(2.5)	25.5

### Param Desai

paramdesai@plindia.com | 91-22-66322259

### Sanketa Kohale

sanketakohale@plindia.com | 91-22-66322426

## Another strong quarter across India & Cayman

### Quick Pointers:

- Reiterated bed expansion plan of ~1,500 beds in India by FY29.
- Higher robotic/cardiac and payer optimization supported realizations, offsetting flat IP volumes.

**Narayana Hrudayalaya (NARH)** reported strong EBITDA of Rs4.4bn (up 44% YoY) adjusted for one time cost, 7% above our estimates driven by robust performance across India and Cayman operations along with consolidation of UK subsidiary. The Cayman business reported profitability of Rs1.88bn (up 42% YoY) adj for CHIL losses. India business reported healthy EBITDA adjusted for NHIC losses, up ~24% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through debottlenecking, refurbishment and better bed mix. In the medium term, NARH intends to add +1,500 beds expansion over next 3 years through greenfield and brownfield across Bengaluru, Kolkata and Raipur. Our FY27E and FY28E EBITDA stands increased by 6-7%. We maintain 'BUY' rating with a TP of Rs2,150/share, based on 23x EV/EBITDA for India business and 15x EV/EBITDA for international operations based on FY28E.

- EBITDA beat led by strong growth across India and Cayman business:** NARH reported EBITDA of Rs3.7bn. During Q3FY26, the UK subsidiary was consolidated for 55 days, contributing revenues of Rs4.9bn and post-Ind AS EBITDA of ~Rs420mn (including losses from the Birmingham unit), translating into ~8.6% EBITDA margins. The quarter included one-time acquisition related expenses of ~Rs 757mn pertaining to the Cayman and UK entities. Adj to this, EBITDA came in at Rs 4.4bn (up 44% YoY) vs we estimated at Rs4.1. Q3 Losses in India insurance and clinics business were to the tune of Rs134mn (Rs 164mn in Q2) while losses from Cayman integrated healthcare (CIHL) were to tune of Rs 131mn (Rs 26mn in Q2). Overall, margins came in at 20.6%, decreased ~245bps YoY. India business adjusted for insurance and clinics, reported EBITDA of Rs2.4bn, up ~27% YoY. India margins improved by ~265bps YoY to 21%. Cayman EBITDA adj for CIHL came in at \$21mn, up 36.5% YoY and 17% QoQ, with OPM improved by 300 bps YoY to ~47%.

- Higher ARPOB aided India growth:** Revenues grew by 61% YoY to Rs21.5bn. ARPOB for India business grew 15% YoY to Rs49,589/day led by better payor mix. IP volumes were flat YoY for India due to capacity constraints in existing hospitals. Cayman revenues increased 28% YoY to \$45mn. Both IP and OP volumes improved by 27% and ~30% YoY, respectively, for Cayman aided by ramping up in new unit. Reported PAT stood at Rs1.3bn; Adjusted for one off PAT came in at Rs2.5bn (up ~32% YoY). NARH's net debt increased by Rs. 19.9bn QoQ to Rs22.3bn.

## Conference Call Highlights:

- **Bed expansion plan** – Management reiterated a cluster-led expansion strategy, with core focus on Bangalore and Kolkata, while selectively scaling up in Raipur. Expansion will be calibrated, avoiding earlier strategy of aggressive pan-India bed addition; emphasis remains on consolidating core markets. Plan includes adding four Da Vinci robotic systems and strengthening oncology capabilities across hospitals. Management highlighted that incremental beds may be temporarily margin dilutive but guided to normalize over time as occupancies ramp up. Overall, NARH has a total 1,535 bed expansion plan in Kolkata, Bengaluru and Raipur in the next 2-3 years; largely greenfield in nature.
- **Capex and its guidance:** Management reiterated the Rs30bn India capex plan over three years through internal accruals, bulk allocation toward Bangalore and Kolkata clusters. UK capex is largely completed; only minor equipment additions pending at Birmingham. Cayman operations remain stable; no major capex planned. No plans to raise equity; capital allocation priority remains India and integration of UK asset. Consolidated net debt to EBITDA to be maintained below 2.5x.
- **Cayman** – Management sees further scope for market share gains and throughput optimization, with limited incremental capex requirements. Technology and process enhancements are being implemented to scale services efficiently and strengthen patient access.
- **Integrated Care (Cayman CIHL)** – The insurance arm is witnessing healthy growth in gross written premiums, aided by increasing corporate/SME penetration. Management is prioritizing underwriting discipline and close monitoring of claims ratios to ensure sustainable profitability.
- **Flagship Units (Bangalore & Kolkata):** Bangalore cluster witnessing strong performance driven by higher realizations and mix shift toward high-end specialties (robotics, cardiac). Kolkata cluster expected to structurally operate at discount to Bangalore due to payer mix differences.
- **Integrated care business (NHIC & NHIL):** Management indicated that the insurance operations are being gradually scaled beyond Bangalore into Kolkata and Raipur. The broader strategy is to deliver an integrated, end-to-end healthcare ecosystem encompassing hospitals, clinics, pharmacy and insurance. The company plans to expand the insurance business in a phased manner across markets where it has a strong on-ground hospital presence, thereby leveraging its existing clinical infrastructure and patient base.
- **CGHS rate change impact:** Mgmt reiterates higher exposure to government schemes as compared to peers. CGHS-linked tariffs account for ~60% of applicable contracts; the latest revision is expected to deliver ~30% package price uplift where applicable. Expect Rs400-500mn positive impact on revenues. Guided lower benefit from Delhi cluster due to lower exposure to CGHS in Delhi cluster limiting impact of rate revisions.

- **Practice Plus (UK Clinics) Acquisition:** Acquisition funded via GBP150mn debt + GBP45mn equity; total consideration of GBP 183mn net of cash. Debt repayment structured as 2+5-year schedule. Mgmt guided Interest cost as per SONIA (Sterling Overnight Index Average) /SOFR (Secured Overnight Financing Rate) + ~200bps. Consolidated depreciation for UK stood at ~Rs 400mn for 2 months; run-rate to be considered going forward. Birmingham hospital is fully operational; losses expected to narrow over ~4 quarters.

**Exhibit 1: Q3FY26 Result Overview (Rs mn) – EBITDA beat led by both India & Cayman operations**

Y/e March	3QFY26	3QFY25	YoY gr. (%)	Q3FY26E	% Var.	2QFY26	QoQ gr. (%)	9MFY26	9MFY25	YoY gr. (%)
<b>Net Sales</b>	<b>21,512</b>	<b>13,346</b>	<b>61.2</b>	<b>23,645</b>	<b>(9.0)</b>	<b>16,438</b>	<b>30.9</b>	<b>53,022</b>	<b>40,422</b>	<b>31.2</b>
COGS	3,815	2,652	43.9	5,202	(26.7)	3,222	18.4	10,095	8,427	19.8
% of Net Sales	17.7	19.9		22.0		19.6		19.0	20.8	
Employee Cost	4,595	2,712	69.4	3,547	29.6	2,991	53.6	10,541	8,235	28.0
% of Net Sales	21.4	20.3		15.0		18.2		19.9	20.4	
Other Expenses	8,673	4,908	76.7	10,739	(19.2)	6,156	40.9	20,519	14,558	40.9
% of Net Sales	40.3	36.8		45.4		37.4		38.7	36.0	
<b>Total</b>	<b>17,082</b>	<b>10,272</b>	<b>66.3</b>	<b>19,488</b>	<b>(12.3)</b>	<b>12,369</b>	<b>38.1</b>	<b>41,154</b>	<b>31,221</b>	<b>31.8</b>
<b>EBITDA</b>	<b>4,429</b>	<b>3,074</b>	<b>44.1</b>	<b>4,157</b>	<b>6.6</b>	<b>4,069</b>	<b>8.9</b>	<b>11,868</b>	<b>9,201</b>	<b>29.0</b>
Margins (%)	20.6	23.0		17.6		24.8		22.4	22.8	
Other Income	232	183	26.9	200	16.0	240	(3.3)	710	653	8.7
Interest	650	366	77.8	580	12.1	423	53.9	1,525	1,057	44.2
Depreciation	1,223	696	75.7	1,000	22.3	875	39.8	2,940	1,960	50.0
<b>PBT</b>	<b>2,789</b>	<b>2,195</b>	<b>27.0</b>	<b>2,777</b>	<b>0.4</b>	<b>3,012</b>	<b>(7.4)</b>	<b>8,113</b>	<b>6,837</b>	<b>18.7</b>
Tax	223	259	(14.0)	444	(49.9)	372	(40.1)	942	893	5.6
Tax rate %	8.0	11.8		16.0		12.4		11.6	13.1	
<b>PAT</b>	<b>2,566</b>	<b>1,936</b>	<b>32.5</b>	<b>2,333</b>	<b>10.0</b>	<b>2,640</b>	<b>(2.8)</b>	<b>7,170</b>	<b>5,944</b>	<b>20.6</b>
Share in (loss)/profit of associate	(19)	-	NA	-	NA	(13)		(36)	-	NA
EO items	(1,266)	-	NA	-	NA	(44)		1,310	-	NA
Minority Interest	-	-	NA	-	NA	-		-	-	NA
<b>Reported PAT</b>	<b>1,281</b>	<b>1,936</b>	<b>(33.9)</b>	<b>2,333</b>	<b>(45.1)</b>	<b>2,583</b>	<b>(50.4)</b>	<b>7,135</b>	<b>5,944</b>	<b>20.0</b>

Source: Company, PL

**Exhibit 2: Break-up of revenues**

Revenues (Rs. mn)	3QFY26	3QFY25	YoY gr. (%)	2QFY26	QoQ gr. (%)	9MFY26	9MFY25	YoY gr. (%)
Cayman	3,864	2,935	31.7	3,512	10.0	10,891	8,032	35.6
CIHL	1,127	-	#DIV/0!	804	40.2	2,384	-	#DIV/0!
India	11,316	10,334	9.5	11,967	(5.4)	34,367	32,194	6.7
NHIC and NHIL	232	107	116.8	190	22.1	566	286	97.9
Practice plus- UK	4,902	-	#DIV/0!	-	#DIV/0!	4,902	-	#DIV/0!
<b>Total Sales</b>	<b>21,441</b>	<b>13,376</b>	<b>60.3</b>	<b>16,473</b>	<b>30.2</b>	<b>53,110</b>	<b>40,512</b>	<b>31.1</b>


Source: Company, PL

**Exhibit 3: Break-up of EBITDA**

EBITDA (Rs. mn)	3QFY26	3QFY25	YoY gr. (%)	2QFY26	QoQ gr. (%)	9MFY26	9MFY25	YoY gr. (%)
Cayman	1,844	1,297	42.2	1,556	18.5	4,937	3,513	40.5
% OPM	47.7	44.2		44.3		45.3	43.7	
CIHL	(131)	-		(26)	405.3	(250)		
India	2,430	1,921	26.5	2,703	(10.1)	7,252	6,090	19.1
% OPM	21.5	18.6		22.6		22.5	18.9	
NHIC and NHIL	(134)	(144)	6.9	(164)	18.3	(491)	(402)	(22.0)
Practice plus- UK	420	-	NA	-	NA	420	-	NA
% OPM	8.6	-	NA	-	NA	8.6	-	NA
<b>Total EBITDA</b>	<b>4,429</b>	<b>3,074</b>	<b>44.1</b>	<b>4,069</b>	<b>8.9</b>	<b>11,868</b>	<b>9,201</b>	


Source: Company, PL

**Exhibit 4: Consolidated OPM declined by ~245bps YoY given UK consolidation**




Source: Company, PL

**Exhibit 5: India margins adj for NHIC losses improved by ~245bps YoY**




Source: Company, PL

**Exhibit 6: Cayman EBITDA growth was at ~52% YoY adj to CIHL losses**




Source: Company, PL

**Exhibit 7: India ARPOB increased ~15% YoY due to better payor mix**




Source: Company, PL

**Exhibit 8: Net debt increased by Rs. 19.9bn QoQ**




Source: Company, PL

**Exhibit 9: Reducing integrated care losses QoQ**



Source: Company, PL

**Exhibit 10: Cayman's insurance business losses increased QoQ**



Source: Company, PL

## Financials

### Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Net Revenues</b>	<b>54,830</b>	<b>78,998</b>	<b>1,06,115</b>	<b>1,19,327</b>
YoY gr. (%)	9.3	44.1	34.3	12.5
Cost of Goods Sold	11,364	17,379	23,345	26,252
Gross Profit	43,466	61,618	82,770	93,075
Margin (%)	79.3	78.0	78.0	78.0
Employee Cost	10,927	12,457	14,201	16,189
Other Expenses	19,775	32,437	46,666	51,382
<b>EBITDA</b>	<b>12,764</b>	<b>16,724</b>	<b>21,903</b>	<b>25,503</b>
YoY gr. (%)	10.8	31.0	31.0	16.4
Margin (%)	23.3	21.2	20.6	21.4
Depreciation and Amortization	2,781	4,158	4,917	5,408
<b>EBIT</b>	<b>9,983</b>	<b>12,567</b>	<b>16,986</b>	<b>20,095</b>
Margin (%)	18.2	15.9	16.0	16.8
Net Interest	1,464	2,189	2,753	2,300
Other Income	920	900	600	700
<b>Profit Before Tax</b>	<b>9,439</b>	<b>11,278</b>	<b>14,833</b>	<b>18,495</b>
Margin (%)	17.2	14.3	14.0	15.5
Total Tax	1,457	1,579	2,522	3,699
Effective tax rate (%)	15.4	14.0	17.0	20.0
<b>Profit after tax</b>	<b>7,982</b>	<b>9,699</b>	<b>12,312</b>	<b>14,796</b>
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>7,898</b>	<b>8,389</b>	<b>12,312</b>	<b>14,796</b>
YoY gr. (%)	0.0	6.2	46.8	20.2
Margin (%)	14.4	10.6	11.6	12.4
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>7,898</b>	<b>8,389</b>	<b>12,312</b>	<b>14,796</b>
YoY gr. (%)	0.0	6.2	46.8	20.2
Margin (%)	14.4	10.6	11.6	12.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	7,898	8,389	12,312	14,796
<b>Equity Shares O/s (m)</b>	<b>204</b>	<b>204</b>	<b>204</b>	<b>204</b>
<b>EPS (Rs)</b>	<b>38.6</b>	<b>41.1</b>	<b>60.2</b>	<b>72.4</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>60,963</b>	<b>91,193</b>	<b>1,01,193</b>	<b>1,11,193</b>
Tangibles	58,718	88,948	98,948	1,08,948
Intangibles	2,245	2,245	2,245	2,245
<b>Acc: Dep / Amortization</b>	<b>19,496</b>	<b>23,654</b>	<b>28,570</b>	<b>33,979</b>
Tangibles	19,496	23,654	28,570	33,979
Intangibles	-	-	-	-
<b>Net fixed assets</b>	<b>41,468</b>	<b>67,540</b>	<b>72,623</b>	<b>77,215</b>
Goodwill	39,222	65,295	70,378	74,969
Non-Current Investments	10,843	10,843	10,843	10,843
Net Deferred tax assets	(559)	(559)	(559)	(559)
Other Non-Current Assets	-	-	-	-
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	1,103	1,731	2,326	2,615
Trade receivables	5,555	7,575	10,175	11,442
Cash & Bank Balance	6,467	5,200	5,305	7,550
Other Current Assets	5,089	7,575	10,175	11,442
<b>Total Assets</b>	<b>72,650</b>	<b>1,02,590</b>	<b>1,13,573</b>	<b>1,23,233</b>
<b>Equity</b>				
Equity Share Capital	2,044	2,044	2,044	2,044
Other Equity	34,220	41,374	52,351	65,695
<b>Total Networth</b>	<b>36,264</b>	<b>43,417</b>	<b>54,395</b>	<b>67,739</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	22,134	42,134	39,134	34,134
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	5,745	8,531	11,536	12,853
Other current liabilities	5,704	5,704	5,704	5,704
<b>Total Equity &amp; Liabilities</b>	<b>72,650</b>	<b>1,02,590</b>	<b>1,13,573</b>	<b>1,23,233</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	9,439	11,278	14,833	18,495
Add. Depreciation	2,781	4,158	4,917	5,408
Add. Interest	1,464	2,189	2,753	2,300
Less Financial Other Income	920	900	600	700
Add. Other	(1,371)	(1,360)	(30)	(30)
Op. profit before WC changes	12,313	16,264	22,473	26,173
Net Changes-WC	(1,185)	(2,349)	(2,790)	(1,507)
Direct tax	(1,270)	(1,579)	(2,522)	(3,699)
<b>Net cash from Op. activities</b>	<b>9,858</b>	<b>12,336</b>	<b>17,162</b>	<b>20,968</b>
Capital expenditures	(10,820)	(30,230)	(10,000)	(10,000)
Interest / Dividend Income	-	-	-	-
Others	(2,434)	-	-	-
<b>Net Cash from Inv. activities</b>	<b>(13,253)</b>	<b>(30,230)</b>	<b>(10,000)</b>	<b>(10,000)</b>
Issue of share cap. / premium	-	-	-	-
Debt changes	7,942	20,000	(3,000)	(5,000)
Dividend paid	(812)	(1,185)	(1,304)	(1,422)
Interest paid	(1,464)	(2,189)	(2,753)	(2,300)
Others	33	-	-	-
<b>Net cash from Fin. activities</b>	<b>5,698</b>	<b>16,626</b>	<b>(7,057)</b>	<b>(8,722)</b>
<b>Net change in cash</b>	<b>2,303</b>	<b>(1,268)</b>	<b>105</b>	<b>2,245</b>
Free Cash Flow	(962)	(17,894)	7,162	10,968

Source: Company Data, PL Research

**Key Financial Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E	
<b>Per Share(Rs)</b>					
EPS		38.6	41.1	60.2	72.4
CEPS		52.3	61.4	84.3	98.9
BVPS		177.4	212.5	266.2	331.5
FCF		(4.7)	(87.6)	35.0	53.7
DPS		5.2	5.8	6.4	7.0
<b>Return Ratio(%)</b>					
RoCE		19.6	17.5	19.0	20.6
ROIC		15.1	12.9	15.7	17.4
RoE		24.5	24.3	25.2	24.2
<b>Balance Sheet</b>					
Net Debt : Equity (x)		0.4	0.9	0.6	0.4
Net Working Capital (Days)		6	4	3	4
<b>Valuation(x)</b>					
PER		47.3	44.6	30.4	25.3
P/B		10.3	8.6	6.9	5.5
P/CEPS		35.0	29.8	21.7	18.5
EV/EBITDA		30.5	24.6	18.6	15.7
EV/Sales		7.1	5.2	3.8	3.4
Dividend Yield (%)		0.3	0.3	0.3	0.4

Source: Company Data, PL Research

**Quarterly Financials (Rs m)**

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
<b>Net Revenue</b>	<b>14,754</b>	<b>15,073</b>	<b>16,438</b>	<b>21,512</b>
YoY gr. (%)	18.4	12.4	20.3	61.2
Raw Material Expenses	3,053	3,058	3,222	3,815
Gross Profit	11,701	12,015	13,216	17,697
Margin (%)	79.3	79.7	80.4	82.3
<b>EBITDA</b>	<b>3,577</b>	<b>3,370</b>	<b>4,069</b>	<b>4,429</b>
YoY gr. (%)	22.9	10.9	31.8	44.1
Margin (%)	24.2	22.4	24.8	20.6
Depreciation / Depletion	825	843	875	1,223
<b>EBIT</b>	<b>2,752</b>	<b>2,526</b>	<b>3,194</b>	<b>3,207</b>
Margin (%)	18.7	16.8	19.4	14.9
Net Interest	407	452	423	650
Other Income	268	238	240	232
<b>Profit before Tax</b>	<b>2,614</b>	<b>2,313</b>	<b>3,012</b>	<b>2,789</b>
Margin (%)	17.7	15.3	18.3	13.0
Total Tax	568	348	372	223
Effective tax rate (%)	21.7	15.0	12.4	8.0
<b>Profit after Tax</b>	<b>2,046</b>	<b>1,965</b>	<b>2,640</b>	<b>2,566</b>
Minority interest	-	-	-	-
Share Profit from Associates	-	(4)	(13)	(19)
<b>Adjusted PAT</b>	<b>1,962</b>	<b>1,961</b>	<b>2,583</b>	<b>1,281</b>
YoY gr. (%)	4.4	(2.7)	29.6	(33.9)
Margin (%)	13.3	13.0	15.7	6.0
Extra Ord. Income / (Exp)	84	-	44	1,266
<b>Reported PAT</b>	<b>2,046</b>	<b>1,961</b>	<b>2,627</b>	<b>2,547</b>
YoY gr. (%)	8.8	(2.7)	31.8	31.5
Margin (%)	13.9	13.0	16.0	11.8
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>2,046</b>	<b>1,961</b>	<b>2,627</b>	<b>2,547</b>
Avg. Shares O/s (m)	204	204	204	204
<b>EPS (Rs)</b>	<b>9.6</b>	<b>9.6</b>	<b>12.6</b>	<b>6.3</b>

Source: Company Data, PL Research

**Key Operating Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E
India hospitals	42,269	60,193	84,535	95,137
Cayman Island	11,861	18,105	20,880	23,490
Others	700	700	700	700

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	06-Jan-26	BUY	2,100	1,901
2	19-Dec-25	BUY	2,100	1,920
3	19-Nov-25	BUY	2,100	1,952
4	04-Nov-25	BUY	2,000	1,783
5	08-Oct-25	BUY	2,000	1,781
6	05-Aug-25	BUY	2,000	1,830
7	08-Jul-25	BUY	1,950	1,990
8	28-May-25	BUY	1,950	1,743
9	08-Apr-25	BUY	1,560	1,644
10	19-Feb-25	BUY	1,560	1,370

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Ajanta Pharma	BUY	3,200	2,768
2	Apollo Hospitals Enterprise	BUY	9,000	7,507
3	Aster DM Healthcare	BUY	715	558
4	Aurobindo Pharma	BUY	1,300	1,124
5	Brigade Enterprises	BUY	1,045	843
6	Cipla	Accumulate	1,440	1,315
7	Divi's Laboratories	Accumulate	6,850	6,387
8	Dr. Reddy's Laboratories	Reduce	1,300	1,157
9	Eris Lifesciences	BUY	1,900	1,553
10	Fortis Healthcare	BUY	1,120	915
11	Global Health	BUY	1,375	1,108
12	HealthCare Global Enterprises	BUY	850	586
13	Indoco Remedies	Hold	325	225
14	Ipca Laboratories	BUY	1,600	1,514
15	J.B. Chemicals & Pharmaceuticals	BUY	2,300	1,927
16	Jupiter Life Line Hospitals	BUY	1,600	1,251
17	Krishna Institute of Medical Sciences	BUY	810	647
18	Lupin	Accumulate	2,400	2,199
19	Max Healthcare Institute	BUY	1,300	1,040
20	Narayana Hrudayalaya	BUY	2,100	1,901
21	Oberoi Realty	Accumulate	1,820	1,647
22	Prestige Estates Projects	BUY	1,880	1,500
23	Rainbow Children's Medicare	BUY	1,550	1,179
24	Sun Pharmaceutical Industries	BUY	1,900	1,595
25	Sunteck Realty	BUY	550	374
26	Torrent Pharmaceuticals	BUY	4,750	4,078
27	Zydus Lifesciences	Accumulate	1,020	887

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock

## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I, Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

## **Prabhudas Lilladher Pvt. Ltd.**

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

[www.plindia.com](http://www.plindia.com)